sion caused by previously implanted defibrillator leads may make the placement of additional leads difficult.
The prevalence of venous occlusion caused by pacemaker leads has been reported to be 6% to 21%. [7] [8] [9] [10] The prevalence of venous occlusion after placement of transvenous defibrillator leads is unknown. Therefore, the purpose of this study was to determine the prevalence of venous occlusion in asymptomatic patients with chronic transvenous defibrillator leads.
Methods

Study design
One hundred fifty-eight patients underwent a defibrillator generator replacement at the University of Michigan Medical Center between September 1996 and October 1999. Because unexpected lead problems are occasionally identified at the time of defibrillator generator replacement and can require the addition of new transvenous leads, 11 one implanting physician performed preoperative bilateral upper extremity venograms in 36 consecutive patients during this 3-year period. Two of the 36 patients had only epicardial leads and 4 had epicardial leads with a transvenous rate-sensing lead; these 6 patients were not included in this study. The remaining 30 patients had a transvenous defibrillator lead and underwent contrast venography with either nonionic contrast media (21 patients), carBefore 1997, all recipients of implantable cardioverter-defibrillators (ICDs) received a single-chamber device. In 1998, 25% of the approximately 41,000 patients undergoing defibrillator implantation in the United States received a dual-chamber system (Warner, personal communication). Since the advent of dualchamber defibrillators, many patients with a previously implanted ventricular defibrillator may be candidates for an upgrade of their device because up to 50% of patients with ventricular defibrillators may benefit from atrial-ventricular sequential pacing. [1] [2] [3] In addition, defibrillator recipients with congestive heart failure or atrial fibrillation are potential candidates for multisite ventricular or atrial pacing. [4] [5] [6] However, central venous occlu-Background Many patients with previously implanted ventricular defibrillators are candidates for an upgrade to a device capable of atrial-ventricular sequential or multisite pacing. The prevalence of venous occlusion after placement of transvenous defibrillator leads is unknown. The purpose of this study was to determine the prevalence of central venous occlusion in asymptomatic patients with chronic transvenous defibrillator leads.
Methods Thirty consecutive patients with a transvenous defibrillator lead underwent bilateral contrast venography of the cephalic, axillary, subclavian, and brachiocephalic veins as well as the superior vena cava before an elective defibrillator battery replacement. The mean time between transvenous defibrillator lead implantation and venography was 45 ± 21 months. Sixteen patients had more than 1 lead in the same subclavian vein. No patient had clinical signs of venous occlusion.
Results One (3%) patient had a complete occlusion of the subclavian vein, 1 (3%) patient had a 90% subclavian vein stenosis, 2 (7%) patients had a 75% to 89% subclavian stenosis, 11 (37%) patients had a 50% to 74% subclavian stenosis, and 15 (50%) patients had no subclavian stenosis.
Conclusions
The low prevalence of subclavian vein occlusion or severe stenosis among defibrillator recipients found in this study suggests that the placement of additional transvenous leads in a patient who already has a ventricular defibrillator is feasible in a high percentage of patients (93%). (Am Heart J 2001;141:813-6.)
bon dioxide (8 patients), or both (1 patient). Carbon dioxide was used in patients with renal insufficiency or a history of adverse reactions to intravenous contrast media. The venography was performed by hand injection of 20 to 40 mL of contrast media in the antecubital veins bilaterally. With the use of digital substraction angiography, the cephalic, axillary, subclavian, and brachiocephalic veins as well as the superior vena cava were visualized in the antero-posterior view. Venous stenoses were categorized by the attending radiologist as no stenosis (<50%), mild stenosis (50% to 74%), moderate stenosis (75% to 89%), severe stenosis (90% to 99%), or total occlusion.
Patient characteristics
The mean age of the patients in this study was 60 ± 15 years (range, 25 to 85 years), and 25 (83%) were men. Seventeen (57%) patients had coronary artery disease, 11 (37%) patients had a dilated cardiomyopathy, and 2 (7%) patients had valvular heart disease. The mean ejection fraction was 0.31 ± 0.12. Seven (23%) patients were chronically anticoagulated with warfarin for atrial fibrillation. No patient required chronic hemodialysis.
Defibrillator system characteristics
The mean time between transvenous defibrillator lead implantation and venography was 45 ± 21 months (range, 2 to 103 months). The configurations of the defibrillator systems are summarized in Table I . Each patient had a transvenous defibrillator lead inserted either through the subclavian vein (n = 23) or the cephalic vein (n = 7). The maximum caliber of the defibrillator lead was 10F in 15 patients, 11F in 8 patients, and 12F in 7 patients (Table II) . Fourteen (47%) patients had no other transvenous leads. The remaining 16 patients had at least 1 additional lead in the same vein. Fourteen of the 16 patients had 1 lead in addition to the defibrillator lead (a superior vena cava shocking coil in 6 patients, an atrial pacing lead in 7 patients, and a ventricular pacing lead in 1 patient). The 2 remaining patients had 2 leads in addition to the defibrillator lead (an atrial and ventricular pacing lead in each patient). Ten patients had a subcutaneous array. Six (20%) of the 30 patients had transvenous permanent pacemaker leads implanted in the contralateral subclavian vein.
Data analysis
Continuous variables are expressed as mean ± SD and are compared by means of a Student t test. Nominal variables were compared by means of a chi-square test or Fisher exact test. A value of P < .05 was considered statistically significant.
Results
Venography revealed a subclavian venous occlusion in 1 (3%) of the 30 patients. This patient had a transvenous defibrillator lead and a superior vena cava shocking coil. One (3%) additional patient was found to have a severe ipsilateral subclavian vein stenosis with collaterals at the defibrillator lead insertion site. This patient had 1 transvenous defibrillator lead and a subcutaneous array. Two (7%) patients had a moderate subclavian stenosis, 11 (37%) patients had a mild subclavian stenosis, and 15 (50%) patients had no stenosis.
A stenosis of ≥75% was found in 2 (14%) of 14 patients with only 1 transvenous lead and in 2 (13%) of 16 patients with more than 1 lead (P = .9). When patients with a ≥75% stenosis were compared with patients with a <75% stenosis, there was no difference in age (60 ± 18 vs 60 ± 15 years; P = 1.0), sex (75% vs 82% male; P = .5), left ventricular ejection fraction (0.26 ± 0.13 vs 0.35 ± 0.12; P = .4), or age of the implanted defibrillator lead (38 ± 10 vs 45 ± 22 months; P = .5). When patients with a ≥75% stenosis were compared with patients with a <75% stenosis, there was also no difference in the proportion who were implanted by a cephalic vein route (1 of 4 patients vs 6 of 26 patients; P = .9), were being treated with warfarin (2 of 4 patients vs 5 of 26 patients; P = .2), received a single-coil ICD lead (1 of 4 patients vs 3 of 26 patients; P = .5), received a polyurethane ICD lead (0 of 4 patients vs 4 of 26 patients; P = .5), received a lead with a maximum diameter >3.5 mm (1 of 4 patients vs 3 of 26 patients; P = .5), or also had contralateral pacemaker leads (2 of patients vs 2 of 26 patients; P = .08).
At the time of defibrillator generator change, 6 (20%) patients underwent an unexpected defibrillator lead revision and 4 (13%) underwent placement of an atrial pacing lead.
Discussion
Main findings
The main finding of this study is that the prevalence of subclavian vein stenosis ≥75% or total occlusion is only 7% among transvenous defibrillator recipients who have no clinical signs of venous occlusion. The mean implant duration of the defibrillator leads in this study was almost 4 years, and most patients had additional transvenous leads. Although defibrillator leads are substantially larger in diameter compared with pacing leads and have exposed shocking coils, the prevalence of venous occlusion is low and is comparable to published data for pacing leads. 
Venous occlusion
The pathophysiology of venous occlusion caused by chronically implanted pacing leads has been described. 12 Endothelial damage and blood flow perturbation give rise to thrombus formation. Thrombus organization results in lead encapsulation. Occlusion occurs predominantly at locations where the lead body lies adjacent to vascular structures or where discontinuities in the lead, such as tines, are present. 13 It is not clear why defibrillator leads in this study were associated with a low incidence of venous occlusion or why the presence of multiple leads did not predict occlusion. The maximal ICD lead diameter in this study was 3.93 mm, but the maximum diameter did not correspond to higher risk of stenosis. There is evidence that polyurethane leads have a lower thrombogenicity and may take longer to encapsulate. 13, 14 Because of the relatively small number of implanted polyurethane leads in our study, no conclusions can be drawn as to whether this translates into a lower occlusion rate in patients with ICD leads. It is possible that individual patient factors may be more important than the characteristics of the transvenous leads in the development of venous occlusion.
Limitations
The number of patients in this study with multiple transvenous leads was small, and no patient had more than 3 transvenous leads. This study does not exclude the possibility that a transvenous defibrillator system with 3 or more leads is associated with a higher incidence of venous occlusion.
Conclusions
The low prevalence (7%) of occlusion or severe stenosis in the subclavian vein among recipients of transvenous defibrillator systems found in this study suggests that the placement of additional transvenous leads in a patient who already has a ventricular defibrillator is feasible in a high percentage of patients (93%). 
